Valuation: Epigenomics AG

Market Cap 789K 905K 745K 677K 1.27M 86.85M 1.27M 8.93M 3.44M 44.16M 3.4M 3.32M 142M P/E 2024
-0.29x
P/E 2025 -2.51x
Enterprise Value 11.76M 13.48M 11.1M 10.08M 18.89M 1.29B 18.97M 133M 51.31M 658M 50.65M 49.52M 2.12B EV / Sales 2024
-
EV / Sales 2025 490x
Free-Float
70.75%
Yield 2024 *
-
Yield 2025 -
1 month-1.64%
3 months+2.86%
6 months-6.25%
1 week 0.9
Extreme 0.9
1.01
1 month 0.9
Extreme 0.9
1.01
Current year 0.84
Extreme 0.84
1.56
1 year 0.84
Extreme 0.84
1.59
3 years 0.5
Extreme 0.5
3.25
5 years 0.5
Extreme 0.5
25.88
10 years 0.5
Extreme 0.5
1,187.36
Manager TitleAgeSince
Investor Relations Contact - -
Corporate Officer/Principal 55 01/02/2024
Director TitleAgeSince
Chairman 58 01/03/2023
Director/Board Member 55 01/06/2020
Director/Board Member 56 05/02/2024
Date Insider Type Main position Quantity % Market Cap. Importance
12/29/22 A Buy

Chief Financial Officer

2,000 0.0122%
9/7/21 A Sell

Director

7,790 0.0637%
2/1/21 A Buy

Chairman

6,355 0.1079%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%+1.12%-72.31% 905K
+2.30%+19.19%+400.00%+88.77% 4.64B
+0.21%+18.22%+114.15%+426.89% 4.57B
-1.91%-2.63%+16.67%+65.06% 3.2B
-0.83%+7.10%+268.95%+571.20% 2.78B
+6.41%+10.68%-21.68%-25.59% 2.27B
+10.59%+13.36%+53.68% - 1.84B
+0.30%+7.13%+27.07%+57.21% 1.11B
-4.13%+6.74%+158.15%-31.33% 1.04B
-3.88%-4.48%-19.56%+36.87% 568M
Average +0.91%+7.22%+99.85%+124.08% 2.2B
Weighted average by Cap. +1.41%+10.81%+155.00%+205.81%

Financials

2024 2025
Net sales - 24K 27.52K 22.66K 20.58K 38.56K 2.64M 38.72K 271K 105K 1.34M 103K 101K 4.32M
Net income -3.35M -3.84M -3.17M -2.87M -5.38M -369M -5.41M -37.91M -14.63M -188M -14.44M -14.12M -603M -314K -360K -296K -269K -504K -34.55M -507K -3.55M -1.37M -17.57M -1.35M -1.32M -56.52M
Net Debt 10.46M 11.99M 9.87M 8.96M 16.8M 1.15B 16.87M 118M 45.63M 585M 45.04M 44.04M 1.88B 10.97M 12.58M 10.36M 9.4M 17.62M 1.21B 17.69M 124M 47.87M 614M 47.24M 46.2M 1.97B
Logo Epigenomics AG
Epigenomics AG is a Germany-based molecular diagnostics company focused on blood-based detection, prognosis and monitoring of cancers using deoxyribonucleic acid (DNA) methylation technology. It develops and commercializes blood-based diagnostic products across multiple cancer indications. The Company's main product is Epi proColon, a blood test for colorectal cancer screening. Along with the blood-based tests the Company offers services related to research, product development, regulatory approval and manufacturing of in-vitro diagnostic (IVD) products. It also offers Epi proLung, a blood-based test that detects the presence of lung cancer in blood plasma. The Company is present in Europe and the United States.
Employees
2
Date Price Change Volume
18/09/26 €0.9000 0.00% 0
17/09/26 €0.9000 0.00% 0
16/09/26 €0.9000 0.00% 341
15/09/26 €0.9000 0.00% 200
14/09/26 €0.9000 0.00% 0

Annual profits - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!